Findings published in the latest issue of Cancer Prevention Research suggest that antiestrogen supplements help decrease the risk of subsequent melanoma in patients with breast cancer.
Findings published in the latest issue of Cancer Prevention Research suggest that antiestrogen supplements help decrease the risk of subsequent melanoma in patients with breast cancer.
Recognizing the increased risk of melanoma among women who have had breast cancer, Dr Christine Bouchardy, from the Geneva Cancer Registry at the Institute for Social and Preventive Medicine, University of Geneva, Switzerland, and colleagues, reviewed data from the Geneva Cancer Registry. They compared melanoma incidence rates for a cohort of breast cancer patients who received antiestrogen therapy with those who did not receive such therapy, as well as with rates found in the general population.
Bouchardy et al. included 7,360 women who had been diagnosed with breast cancer between 1980 and 2005 in the analysis. The women were followed until 2008. Just over half (54%) of the women in the analysis received antiestrogen therapy. Bouchardy and colleagues found that 34 of the women in the study developed cutaneous melanoma.
For the women who received antiestrogen therapy, the risk of developing melanoma was nearly identical to that of the general population (standardized incidence ratio=0.98). However, the women who did not receive the therapy had a standardized incidence ration of 1.60, or a 60% increased risk of developing melanoma.
Based on their research, Bouchardy and colleagues noted that antiestrogen supplementation in breast cancer may reduce the risk of subsequent cutaneous melanoma. “This study suggests that antiestrogen therapy modifies the risk of melanoma after breast cancer,” the authors wrote.
However, the authors cautioned that widespread use of antiestrogen therapy may be premature. “Although our results are in agreement with the hypothesis that estrogens could play a role in melanoma occurrence, they need to be replicated in a larger study with data on potential confounders,” they explained.
Related Content
OBGYN.net Breast Health and Breast Care Beta Blocker Use May Confer Protective Properties for Women With Breast Cancer
Reference:
Huber C, Bouchardy C, Schaffar R, et al. Antiestrogen therapy for breast cancer modifies the risk of subsequent cutaneous melanoma. Cancer Prev Res (Phila). 2012;5(1):82-8.
Exogenous hormones and patients at increased risk for breast cancer
October 17th 2023This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.
Read More
Hormone replacement therapy does not increase breast cancer recurrence, mortality in survivors
July 20th 2022An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.
Read More